Comparison of the Antinociceptive Profiles of Gabapentin and 3-methylgabapentin in Rat Models of Acute and Persistent Pain: Implications for Mechanism of Action
Overview
Affiliations
The anticonvulsant gabapentin (GBP) has been shown effective for the treatment of neuropathic pain, although its mechanism of action remains unclear. A recent report has suggested that binding to the alpha(2)delta subunit of voltage-gated calcium channels contributes to its antinociceptive effect, based on the stereoselective efficacy of two analogs: (1S,3R)3-methylgabapentin (3-MeGBP) (IC(50) = 42 nM), which is effective in neuropathic pain models; and (1R,3R)3-MeGBP (IC(50) > 10,000 nM), which is ineffective (Field et al., 2000). The present study was designed to further examine the profiles of GBP and 3-MeGBP in rat models of acute and persistent pain. Systemic administration of GBP or (1S,3R)3-MeGBP inhibited tactile allodynia in the spinal nerve ligation model of neuropathic pain, whereas (1R,3R)3-MeGBP was ineffective. The antiallodynic effect of GBP, but not (1S,3R)3-MeGBP, was blocked by i.t. injection of the GABA(B) receptor antagonist [3-[[(3,4-dichlorophenyl)methyl]amino]propyl](diethoxymethyl)phosphinic acid (CGP52432). Systemic GBP or (1S,3R)3-MeGBP also inhibited the second phase of formalin-evoked nociceptive behaviors, whereas (1R,3R)3-MeGBP was ineffective. However, both (1S,3R)3-MeGBP and (1R,3R)3-MeGBP, but not GBP, inhibited first phase behaviors. In the carrageenan model of inflammatory pain, systemic GBP or (1R,3R)3-MeGBP failed to inhibit thermal hyperalgesia, whereas (1S,3R)3-MeGBP had a significant, albeit transient, effect. Systemic (1S,3R)3-MeGBP, but not GBP or (1R,3R)3-MeGBP, also produced an antinociceptive effect in the warm water tail withdrawal test of acute pain. These data demonstrate that GBP and 3-MeGBP display different antinociceptive profiles, suggesting dissimilar mechanisms of antinociceptive action. Thus, the stereoselective efficacy of 3-MeGBP, presumably related to alpha(2)delta binding, likely does not completely account for the mechanism of action of GBP.
TREK1 channel activation as a new analgesic strategy devoid of opioid adverse effects.
Busserolles J, Ben Soussia I, Pouchol L, Marie N, Meleine M, Devilliers M Br J Pharmacol. 2020; 177(20):4782-4795.
PMID: 32851651 PMC: 7520446. DOI: 10.1111/bph.15243.
Woo S, Chung G, Bae H, Kim S Toxins (Basel). 2019; 11(8).
PMID: 31430923 PMC: 6723753. DOI: 10.3390/toxins11080477.
Sadler K, Langer S, Menzel A, Moehring F, Erb A, Brandow A Br J Haematol. 2019; 187(2):246-260.
PMID: 31247672 PMC: 6786911. DOI: 10.1111/bjh.16067.
Deng M, Chen S, Chen H, Pan H Anesthesiology. 2019; 130(5):804-819.
PMID: 30839350 PMC: 6469992. DOI: 10.1097/ALN.0000000000002648.
Smith M, Woodhead J, Handy L, Pruess T, Vanegas F, Grussendorf E Neurochem Res. 2017; 42(7):1995-2010.
PMID: 28508174 DOI: 10.1007/s11064-017-2286-9.